133 related articles for article (PubMed ID: 21793633)
1. Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells.
Dige A; Hvas CL; Deleuran B; Kelsen J; Bendix-Struve M; Dahlerup JF; Agnholt J
Scand J Gastroenterol; 2011 Oct; 46(10):1206-14. PubMed ID: 21793633
[TBL] [Abstract][Full Text] [Related]
2. Lack of correlation between Treg quantification assays in inflammatory bowel disease patients.
Brandhorst G; Petrova DT; Weigand S; Eberle C; von Ahsen N; Schmitz J; Schultze FC; Raddatz D; Karaus M; Oellerich M; Walson PD
World J Gastroenterol; 2015 Mar; 21(11):3325-9. PubMed ID: 25805940
[TBL] [Abstract][Full Text] [Related]
3. Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease.
Hvas CL; Kelsen J; Agnholt J; Dige A; Christensen LA; Dahlerup JF
Autoimmunity; 2010 Jun; 43(4):325-33. PubMed ID: 20298123
[TBL] [Abstract][Full Text] [Related]
4. Number and phenotype of rheumatoid arthritis patients' CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept.
Blache C; Lequerré T; Roucheux A; Beutheu S; Dedreux I; Jacquot S; Le Loët X; Boyer O; Vittecoq O
Rheumatology (Oxford); 2011 Oct; 50(10):1814-22. PubMed ID: 21791546
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
6. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
[TBL] [Abstract][Full Text] [Related]
7. [The subpopulation CD4(+); CD25(+); Foxp3(+);/CD127(low/-); regulatory T cells in peripheral blood of HIV-infected patients correlated with disease progression].
Chen YL; Chen XR; Qin LX; Yang YF; Tang YM
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Nov; 28(11):1188-91. PubMed ID: 23127412
[TBL] [Abstract][Full Text] [Related]
8. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
Sandborn WJ; Colombel JF; D'Haens G; Plevy SE; Panés J; Robinson AM; Pollack PF; Zhou Q; Castillo M; Thakkar RB
Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
10. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Panaccione R; Schreiber S; Byczkowski D; Li J; Kent JD; Pollack PF
Gastroenterology; 2007 Jan; 132(1):52-65. PubMed ID: 17241859
[TBL] [Abstract][Full Text] [Related]
12. Therapy with anti-TNFα antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases.
Boschetti G; Nancey S; Sardi F; Roblin X; Flourié B; Kaiserlian D
Inflamm Bowel Dis; 2011 Jan; 17(1):160-70. PubMed ID: 20848510
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of Adalimumab in Crohn's disease].
Serghini M; Haddad W; Jeddi H; Karoui S; Ben Mustapha N; Kallel L; Fekih M; Matri S; Boubaker J; Filali A
Tunis Med; 2012 Feb; 90(2):101-7. PubMed ID: 22407620
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response.
Kikuchi J; Hashizume M; Kaneko Y; Yoshimoto K; Nishina N; Takeuchi T
Arthritis Res Ther; 2015 Jan; 17(1):10. PubMed ID: 25604867
[TBL] [Abstract][Full Text] [Related]
15. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
Tonelli F; Giudici F; Asteria CR
Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease.
Clerici M; Cassinotti A; Onida F; Trabattoni D; Annaloro C; Della Volpe A; Rainone V; Lissoni F; Duca P; Sampietro G; Fociani P; Vago G; Foschi D; Ardizzone S; Deliliers GL; Porro GB
Dig Liver Dis; 2011 Dec; 43(12):946-52. PubMed ID: 21907652
[TBL] [Abstract][Full Text] [Related]
18. Increased levels of circulating Th17 cells in quiescent versus active Crohn's disease.
Dige A; Støy S; Rasmussen TK; Kelsen J; Hvas CL; Sandahl TD; Dahlerup JF; Deleuran B; Agnholt J
J Crohns Colitis; 2013 Apr; 7(3):248-55. PubMed ID: 22784949
[TBL] [Abstract][Full Text] [Related]
19. [Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].
Lazebnik LB; Sagynbaeva VÉ
Eksp Klin Gastroenterol; 2013; (7):18-22. PubMed ID: 24772870
[TBL] [Abstract][Full Text] [Related]
20. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.
Kiss LS; Szamosi T; Molnar T; Miheller P; Lakatos L; Vincze A; Palatka K; Barta Z; Gasztonyi B; Salamon A; Horvath G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovasz BD; Vegh Z; Golovics PA; Szathmari M; Papp M; Lakatos PL;
Aliment Pharmacol Ther; 2011 Oct; 34(8):911-22. PubMed ID: 21883326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]